New from XDx – Announcing…
AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!
For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant.
As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant.
When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.
Freedom from Future Rejection
A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)
1.
The CARGO II study, underway at nineteen transplant centers from three continents, was initiated in April 2005 to confirm and extend the results of the Cardiac Allograft Rejection Gene expression Observational (CARGO) study in an international setting. The original CARGO study, begun in 2001, was a sample and data collection effort undertaken at eight major U.S. transplant centers. Using CARGO study data, XDx developed and validated AlloMap molecular expression testing, a multi-gene expression assay that detects the absence of acute cellular rejection in clinically stable cardiac allograft recipients. AlloMap testing was launched by the CLIA-certified XDx Reference Laboratory in November 2004.
